Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study to determine the efficacy and safety of Antistax® film coated tablets in improving microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Antistax® | Experimental | 1 x 360 mg for 42 days |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antistax® | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Changes from baseline in the resting flux | measured in the frequency range 10-37 kHz on the skin of the inside lower leg using the Laser Doppler Fluxmetry | Baseline, after 6 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes from baseline in the resting flux | measured in the frequency range 10-37 kHz | Baseline, after 3 weeks of treatment |
| Changes in the resting flux | measured in the frequency range <10 kHz |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Concomitant disease(s) exclusion criteria:
Previous treatment(s) exclusion criteria:
Concomitant treatment/non-drug therapy exclusion criteria:
Other exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33141449 | Derived | Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014689 | Venous Insufficiency |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C522873 | Antistax |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, after 3 and 6 weeks of treatment |
| Changes in the combined resting fluxes (<37 kHz) | Baseline, after 3 and 6 weeks of treatment |
| Changes in the transcutaneous oximetry (TcPO2) | measured on the inside lower leg of the more CVI-affected leg | Baseline, after 3 and 6 weeks of treatment |
| Change from baseline in the calf circumference of the most affected leg | Baseline, after 3 and 6 weeks of treatment |
| Change from baseline in the ankle circumference of the most affected leg | Baseline, after 3 and 6 weeks of treatment |
| Change from baseline in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS) | Baseline, after 3 and 6 weeks of treatment |
| Global efficacy assessment by patient on a 4-point verbal rating scale (VRS) | after 6 weeks of treatment |
| Global efficacy assessment by investigator on a 4-point VRS | after 6 weeks of treatment |
| Number of patients with adverse events | up to 16 weeks |
| Number of patients with clinically relevant changes in laboratory values | Baseline, up to 16 weeks |
| Number of patients with clinically significant changes in vital signs | Baseline, up to 16 weeks |
| Global tolerability assessment by investigator on a 4-point VRS | after 6 weeks of treatment |
| Global tolerability assessment by patient on a 4-point VRS | after 6 weeks of treatment |